Protagonist Therapeutics Competitors and Similar CompaniesClear all
Protagonist Therapeutics's competitors and similar companies include Rgenta, Novartis, Pfizer and Cellectar Biosciences.
 Protagonist Therapeutics Protagonist Therapeutics is a biopharmaceutical company engaged in discovering and developing peptide-based therapeutic drugs. |  Rgenta Rgenta Therapeutics is a company developing RNA-targeting medicines focused on oncology and neurological disorders. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Pfizer Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products. |  Cellectar Biosciences Cellectar Biosciences (formerly Novelos Therapeutics) is a clinical biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. | |
Founding Date | Founding Date 2006 | Founding Date 2020 | Founding Date 1996 | Founding Date 1849 | Founding Date 1996 |
Type | Type Public | Type Private | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Newark, US HQ Saint Lucia, AU | Locations Woburn, US HQ | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New York, US HQ Buenos Aires, AR Villa Adelina, AR Footscray, AU Mulgrave, AU Sydney, AU Wien, AT see more | Locations Florham Park, US HQ |
Employees | Employees 12613% increase | Employees 299% decrease | Employees 75,883 | Employees 81,0008% decrease | Employees 1145% decrease |
Valuation ($) | Valuation ($) 2.9 b | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 163.9 b | Valuation ($) 73.7 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $46m (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) $62.6b (FY, 2025) | Revenue (est.) N/A |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods $8.4b (FY, 2025) | Cost of goods $16.1b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $49.8b (FY, 2025) | Gross profit $46.5b (FY, 2025) | Gross profit N/A |
Net income | Net income ($130.1m) (FY, 2025) | Net income N/A | Net income $14b (FY, 2025) | Net income $7.8b (FY, 2025) | Net income ($21.8m) (FY, 2025) |
Operating ⚠ | |||||
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products 32 (FY, 2024) | Phase III Trials Products N/A |
Registration Phase Products | Registration Phase Products N/A | Registration Phase Products N/A | Registration Phase Products 8 (FY, 2022) | Registration Phase Products 5 (FY, 2024) | Registration Phase Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 28.3m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Rgenta
HQ
Woburn, US
Employees
29↓ 9% decrease
Rgenta Therapeutics is a company developing RNA-targeting medicines focused on oncology and neurological disorders.
View companyNovartis
HQ
Basel, CH
Employees
75,883
Novartis is a company that researches, develops, manufactures, and markets healthcare products.
View companyPfizer
HQ
New York, US
Employees
81,000↓ 8% decrease
Pfizer is a research-based biopharmaceutical company engaged in the discovery, development, manufacture, and distribution of healthcare products.
View companyCellectar Biosciences
HQ
Florham Park, US
Employees
11↓ 45% decrease
Cellectar Biosciences (formerly Novelos Therapeutics) is a clinical biopharmaceutical company that focuses on the discovery, development, and commercialization of drugs for the treatment of cancer.
View company